SUPPLEMENTARY FIG. S1. Characterization of dual-labeled fluorescent small interfering RNA/cyclodextrin-containing polymer nanoparticle (siRNA/CDP NPs). (A) AlexaFluor 350 (AF350) is conjugated to the terminal ends of the CDP in place of imidazole. (B) The presence of 80% mole% Cy3-siRNA and/or 80% mole % AF350-CDP did not affect siRNA encapsulation. (C) siRNA/CDP NPs formulated with an 80% fluorescently labeled fraction of CDP and siRNA are similar in size, zeta potential, and stability to the standard particle formulation. To measure salt stability, particle size was tracked by dynamic light scattering for 5 minutes, then phosphate-buffered saline (PBS) was added to make 1× PBS solution, the sample was then immediately put back into the DLS machine and tracked for a further 10 minutes.